|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-25.32/-20.49
|
企业价值
115.96M
|
资产负债 |
每股账面净值
-15.72
|
现金流量 |
现金流量率
--
|
损益表 |
收益
8.57M
|
每股收益
0.79
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/24 12:43 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform). |